Old Web
English
Sign In
Acemap
>
authorDetail
>
Kazuo Sato
Kazuo Sato
Pfizer
Medicine
Confidence interval
Internal medicine
Neuroendocrine tumors
Sunitinib
3
Papers
15
Citations
0.00
KQI
Citation Trend
Filter By
Interval:
1900~2024
1900
2024
Author
Papers (3)
Sort By
Default
Most Recent
Most Early
Most Citation
No data
Journal
Conference
Others
Real-world use of temsirolimus in Japanese patients with unresectable or metastatic renal cell carcinoma: recent consideration based on the results of a post-marketing, all-case surveillance study.
2020
Japanese Journal of Clinical Oncology
Shigeru Sugiyama
Kazuo Sato
Yoshiyuki Shibasaki
Yutaka Endo
Taku Uryu
Yasuharu Toyoshima
Mototsugu Oya
Naoto Miyanaga
Nagahiro Saijo
Akihiko Gemma
Hideyuki Akaza
Show All
Source
Cite
Save
Citations (2)
Efficacy and safety of sunitinib in Japanese patients with progressive, advanced/metastatic, well-differentiated, unresectable pancreatic neuroendocrine tumors: final analyses from a Phase II study.
2019
Japanese Journal of Clinical Oncology
Tetsuhide Ito
Masayuki Tori
Satoshi Hashigaki
Nobuyuki Kimura
Kazuo Sato
Emiko Ohki
Akira Sawaki
Takuji Okusaka
Show All
Source
Cite
Save
Citations (7)
Real-world use of sunitinib in Japanese patients with pancreatic neuroendocrine tumors: results from a post-marketing surveillance study
2019
Cancer Chemotherapy and Pharmacology
Kazuo Sato
Yasuharu Toyoshima
Shiho Moriyama
Yutaka Endo
Tetsuhide Ito
Emiko Ohki
Show All
Source
Cite
Save
Citations (6)
1
map